Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- Long-Term Follow-Up of Lumbar Total Disc Replacement No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Outcomes of the Convergent Procedure for the Treatment of Persistent Atrial Fibrillation No ClinicalTrials.gov identifier reported
- Long Term Follow-Up of Participants Exposed to Gsk3377794 (Ny-Eso-1C25 No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product NCT02698579
- Long-term follow-up of patients enrolled in TOWER study No ClinicalTrials.gov identifier reported
- Long Term Follow Up of Patients Exposed to Lentiviral Based Cd19 Directed Car T Cell Therapy No ClinicalTrials.gov identifier reported
- Long Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derviced Factor VIII Containing ADAMTS13 No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product NCT02698579
- Longterm Follow-Up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product No ClinicalTrials.gov identifier reported
- Longterm Follow-Up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product No ClinicalTrials.gov identifier reported
- Longterm Follow-Up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product No ClinicalTrials.gov identifier reported
- Longterm Follow-Up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product No ClinicalTrials.gov identifier reported
- Longterm Follow-Up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product No ClinicalTrials.gov identifier reported
- Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents No ClinicalTrials.gov identifier reported
- Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents No ClinicalTrials.gov identifier reported
- Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents No ClinicalTrials.gov identifier reported
- Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents No ClinicalTrials.gov identifier reported
- Longterm Follow up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Longterm Follow up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Longterm Follow up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Longterm Follow up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector No ClinicalTrials.gov identifier reported
- Long-term Follow-up of Subjects With Transfusion-Dependent ?-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy NCT02633943
- Long-Term Follow-up of the Sidus Stem-Free Shoulder Arthroplasty System No ClinicalTrials.gov identifier reported
- Long Term Follow Up of the St. Jude Medical Trifecta Valve NCT01593917
- Long Term Follow Up of the St. Jude Medical Trifecta Valve No ClinicalTrials.gov identifier reported
- Long Term Follow Up of the St. Jude Medical Trifecta Valve NCT01593917
- Long-Term Follow-Up on Laa Exclusion Using Atriclip No ClinicalTrials.gov identifier reported
- Longterm Followup on Laa Exclusion Using Atriclip No ClinicalTrials.gov identifier reported
- Longterm Followup on Laa Exclusion Using Atriclip NCT01984346
- Long Term Follow Up Protocol for Nicord\Cordin (Omidubicel) Patients NCT02039557
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells No ClinicalTrials.gov identifier reported
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells NCT03435796
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. NCT03435796
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (GC-LTFU-001) No ClinicalTrials.gov identifier reported
- Long-Term Follow-Up Protocol for Subjects Treated No ClinicalTrials.gov identifier reported
- Long-Term Follow-Up Protocol for Subjects Treated With Car T Cells NCT03435796